Background: Lung cancer accounts for one in five cancer deaths worldwide and mutations in
the gene encoding for the Kirsten rat sarcoma (KRAS) oncoprotein define the largest …

Non-small-cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) mutations has
notoriously challenged oncologists and researchers for three notable reasons:(1) the …

KRAS-mutated non–small cell lung cancer (NSCLC) is the most common genetically altered
subtype of NSCLC, yet targeted therapies remain limited. Multiple studies have investigated …

The KRAS mutation remains the most common driver mutation in patients with non-small cell
lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation …

KRAS is the most frequent oncogene in non-small cell lung cancer (NSCLC), a molecular
subset characterized by historical disappointments in targeted treatment approaches such …

For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to
therapeutic strategies based on personalized medicine owing to the complexity of designing …

Purpose: KRAS-mutant lung cancers have been recalcitrant to treatments including those
targeting the MAPK pathway. Covalent inhibitors of KRAS p. G12C allele allow for direct and …

The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class
of drugs for an old target—a narrative review - PMC Back to Top Skip to main content NIH NLM …

KRAS mutations are the most frequent molecular abnormalities found in one out of four
nonsmall cell lung cancers (NSCLC). Their incidence increases in cases of …

Lung cancer is the most frequent cancer with an aggressive clinical course and high
mortality rates. Most cases are diagnosed at advanced stages when treatment options are …